

BRASKEM SA
Form 6-K
August 10, 2016

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16
OR 15D-16 OF THE SECURITIES EXCHANGE ACT OF 1934**

For the month of August, 2016
(Commission File No. 1-14862)

BRASKEM S.A.
(Exact Name as Specified in its Charter)

N/A
(Translation of registrant's name into English)

Rua Eteno, 1561, Polo Petroquimico de Camacari
Camacari, Bahia - CEP 42810-000 Brazil
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1).

Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7).

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to
the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _____.

ATTACHMENT II “B”

CONSOLIDATED FORM

Management and Related Persons’ Trading of Securities Issued by the Company

Article 11 – CVM Instruction #358/2002

In July/2016 no transactions involving securities and derivatives were executed, pursuant to Article 11 - CVM Instruction #358/2002.

Company’s Name: Braskem S.A.

Group and

Related
Persons

(X) Board of Directors () Management

() Fiscal Council

() Controlling
Shareholders

Opening Balance

Securities/ Derivatives	Securities Characteristics (2)	Quantity	Interest %	
			Same Type/ Class	Total
Share	Common Share	0	-	-
Share	Class “A” Preferred Share	76,526	0.02%	0.01%

Closing Balance

Securities/ Derivatives	Securities Characteristics (2)	Quantity	Interest %	
			Same Type/ Class	Total
Share	Common Share	0	-	-
Share	Class “A” Preferred Share	76,526	0.02%	0.01%

Closing Balance

1

ATTACHMENT II "B"

CONSOLIDATED FORM

Management and Related Persons' Trading of Securities Issued by the Company

Article 11 – CVM Instruction #358/2002

In July/2016 no transactions involving securities and derivatives were executed, pursuant to Article 11 - CVM Instruction #358/2002.

Company's Name: Braskem S.A.

Group and
Related
Persons

Board of Directors

Management

Fiscal Council

Controlling
Shareholders

Opening Balance

Securities/ Derivatives	Securities Characteristics (2)	Quantity	Interest %	
			Same Type/ Class	Total
Share	Common Share	0	-	-
Share	Class "A" Preferred Share	510	0.0001%	0.0001%

Closing Balance

Securities/ Derivatives	Securities Characteristics (2)	Quantity	Interest %	
			Same Type/ Class	Total
Share	Common Share	0	-	-
Share	Class "A" Preferred Share	510	0.0001%	0.0001%

ATTACHMENT II "B"

CONSOLIDATED FORM

Management and Related Persons' Trading of Securities Issued by the Company

Article 11 – CVM Instruction #358/2002

In July/2016 no transactions involving securities and derivatives were executed, pursuant to Article 11 - CVM Instruction #358/2002.

Company's Name: Braskem S.A.

Group and

Related
Persons

Board of Directors

Management

Fiscal Council

Controlling
Shareholders

Opening Balance

Securities/ Derivatives	Securities Characteristics (2)	Quantity	Interest %	
			Same Type/ Class	Total
Share	Common Share	0	-	-
Share	Class "A" Preferred Share	0	-	-

Closing Balance

Securities/ Derivatives	Securities Characteristics (2)	Quantity	Interest %	
			Same Type/ Class	Total
Share	Common Share	0	-	-
Share	Class "A" Preferred Share	0	-	-

ATTACHMENT II "B"

CONSOLIDATED FORM

Management and Related Persons' Trading of Securities Issued by the Company

Article 11 – CVM Instruction #358/2002

In July/2016 no transactions involving securities and derivatives were executed, pursuant to Article 11 - CVM Instruction #358/2002.

Company's Name: Braskem S.A.

Group and
Related
Persons

Board of Directors

Management

Fiscal Council

Controlling
Shareholders

Opening Balance

Securities/ Derivatives	Securities Characteristics (2)	Quantity	Interest %	
			Same Type/ Class	Total
Share	Common Share	226,334,623	50.11%	28.39%
Share	Class "A" Preferred Share	79,182,498	22.95%	9.93%

Closing Balance

Securities/ Derivatives	Securities Characteristics (2)	Quantity	Interest %	
			Same Type/ Class	Total
Share	Common Share	226,334,623	50.11%	28.39%
Share	Class "A" Preferred Share	79,182,498	22.95%	9.93%

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: August 10, 2016

BRASKEM S.A.

By: /s/ Pedro Van Langendonck Teixeira de Freitas

Name: Pedro Van Langendonck Teixeira de Freitas
Title: Chief Financial Officer

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements. These statements are statements that are not historical facts, and are based on management's current view and estimates of future economic circumstances, industry conditions, company performance and financial results. The words "anticipates", "believes", "estimates", "expects", "plans" and similar expressions, as they relate to the company, are intended to identify forward-looking statements. Statements regarding the declaration or payment of dividends, the implementation of principal operating and financing strategies and capital expenditure plans, the direction of future operations and the factors or trends affecting financial condition, liquidity or results of operations are examples of forward-looking statements. Such statements reflect the current views of management and are subject to a number of risks and uncertainties. There is no guarantee that the expected events, trends or results will actually occur. The statements are based on many assumptions and factors, including general economic and market conditions, industry conditions, and operating factors. Any changes in such assumptions or factors could cause actual results to differ materially from current expectations.